No Data
Novo Nordisk's New Weight-loss Drug Works Better, but Not as Well as Expected
Health Care Roundup: Market Talk
Did Novo-Nordisk A/S fall, leaving Eli Lilly and Co to dominate the weight loss medication market?
Novo-Nordisk A/S faced a "Waterloo," with new drug effects falling short of expectations, causing a dramatic drop in stock prices. The landscape of the weight loss drug market is quietly changing; will Eli Lilly and Co become a sole oligopoly?
FDA Approves Alhemo Injection as Once-daily Prophylactic Treatment to Prevent or Reduce the Frequency of Bleeding Episodes for Adults and Children 12 Years of Age and Older With Hemophilia A or B With Inhibitors
Top Gap Ups and Downs on Friday: NVO, BABA, INFY and More
Novo Nordisk Stock Crashes on Obesity Drug Data. It's a Win for Eli Lilly. -- Barrons.com
